vs
Side-by-side financial comparison of SAUL CENTERS, INC. (BFS) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $75.1M, roughly 1.4× SAUL CENTERS, INC.). SAUL CENTERS, INC. runs the higher net margin — 8.7% vs -29.4%, a 38.1% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 10.6%).
Saul Centers, Inc. is a self-administered real estate investment trust (REIT) headquartered in the United States. It primarily owns, operates, and develops high-quality shopping centers, mixed-use properties, and multifamily residential assets, with its core portfolio concentrated in the Washington D.C. metropolitan area and other select high-growth U.S. regional markets.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
BFS vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $103.7M |
| Net Profit | $6.5M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 65.4% | -31.7% |
| Net Margin | 8.7% | -29.4% |
| Revenue YoY | 10.6% | 16.9% |
| Net Profit YoY | -19.6% | 3.4% |
| EPS (diluted) | $0.15 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.1M | $103.7M | ||
| Q3 25 | $72.0M | — | ||
| Q2 25 | $70.8M | — | ||
| Q1 25 | $71.9M | — | ||
| Q4 24 | $67.9M | — | ||
| Q3 24 | $67.3M | — | ||
| Q2 24 | $66.9M | — | ||
| Q1 24 | $66.7M | — |
| Q4 25 | $6.5M | $-30.5M | ||
| Q3 25 | $10.5M | — | ||
| Q2 25 | $10.7M | — | ||
| Q1 25 | $9.8M | — | ||
| Q4 24 | $8.1M | — | ||
| Q3 24 | $14.5M | — | ||
| Q2 24 | $14.4M | — | ||
| Q1 24 | $13.6M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 73.6% | — | ||
| Q2 24 | 74.2% | — | ||
| Q1 24 | 72.8% | — |
| Q4 25 | 65.4% | -31.7% | ||
| Q3 25 | 69.1% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 66.5% | — | ||
| Q4 24 | 82.9% | — | ||
| Q3 24 | 72.8% | — | ||
| Q2 24 | 75.0% | — | ||
| Q1 24 | 72.4% | — |
| Q4 25 | 8.7% | -29.4% | ||
| Q3 25 | 14.6% | — | ||
| Q2 25 | 15.1% | — | ||
| Q1 25 | 13.6% | — | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 21.5% | — | ||
| Q2 24 | 21.6% | — | ||
| Q1 24 | 20.4% | — |
| Q4 25 | $0.15 | $-0.50 | ||
| Q3 25 | $0.32 | — | ||
| Q2 25 | $0.33 | — | ||
| Q1 25 | $0.29 | — | ||
| Q4 24 | $0.22 | — | ||
| Q3 24 | $0.48 | — | ||
| Q2 24 | $0.48 | — | ||
| Q1 24 | $0.45 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.7M | $197.9M |
| Total DebtLower is stronger | $468.4M | — |
| Stockholders' EquityBook value | $307.8M | $456.1M |
| Total Assets | $2.2B | $638.1M |
| Debt / EquityLower = less leverage | 1.52× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.7M | $197.9M | ||
| Q3 25 | $11.8M | — | ||
| Q2 25 | $5.3M | — | ||
| Q1 25 | $6.5M | — | ||
| Q4 24 | $10.3M | — | ||
| Q3 24 | $7.2M | — | ||
| Q2 24 | $6.9M | — | ||
| Q1 24 | $7.1M | — |
| Q4 25 | $468.4M | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $455.8M | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $307.8M | $456.1M | ||
| Q3 25 | $316.6M | — | ||
| Q2 25 | $322.4M | — | ||
| Q1 25 | $328.4M | — | ||
| Q4 24 | $335.8M | — | ||
| Q3 24 | $341.8M | — | ||
| Q2 24 | $345.7M | — | ||
| Q1 24 | $347.1M | — |
| Q4 25 | $2.2B | $638.1M | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.0B | — |
| Q4 25 | 1.52× | — | ||
| Q3 25 | 5.02× | — | ||
| Q2 25 | 4.85× | — | ||
| Q1 25 | 4.70× | — | ||
| Q4 24 | 1.36× | — | ||
| Q3 24 | 4.37× | — | ||
| Q2 24 | 4.17× | — | ||
| Q1 24 | 4.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $99.8M | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | 15.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $99.8M | $-24.8M | ||
| Q3 25 | $20.6M | — | ||
| Q2 25 | $26.6M | — | ||
| Q1 25 | $30.4M | — | ||
| Q4 24 | $121.2M | — | ||
| Q3 24 | $26.5M | — | ||
| Q2 24 | $32.1M | — | ||
| Q1 24 | $33.8M | — |
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-28.3M | — | ||
| Q2 24 | $-12.5M | — | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -42.1% | — | ||
| Q2 24 | -18.7% | — | ||
| Q1 24 | -17.6% | — |
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 81.5% | — | ||
| Q2 24 | 66.7% | — | ||
| Q1 24 | 68.3% | — |
| Q4 25 | 15.35× | — | ||
| Q3 25 | 1.97× | — | ||
| Q2 25 | 2.48× | — | ||
| Q1 25 | 3.10× | — | ||
| Q4 24 | 14.98× | — | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | 2.22× | — | ||
| Q1 24 | 2.48× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BFS
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
